Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shumei Chia

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Nature Communications|September 7, 2017
Phenotype-driven precision oncology as a guide for clinical decisions one patient at a timeShumei Chia, Joo-Leng Low, Xiaoqian Zhang, et al.
The Lancet. Oncology|January 18, 2025
Pembrolizumab with or without bevacizumab in platinum-resistant recurrent or metastatic nasopharyngeal carcinoma: a randomised, open-label, phase 2 trialWan-Qin Chong, Jia-Li Low, Joshua K Tay, et al.
Cell Reports. Medicine|April 5, 2025
CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancerShumei Chia, Justine Jia Wen Seow, Rafael Peres da Silva, et al.
Nature Genetics|June 30, 2022
Single-cell and bulk transcriptome sequencing identifies two epithelial tumor cell states and refines the consensus molecular classification of colorectal cancerIgnasius Joanito, Pratyaksha Wirapati, Nancy Zhao, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Nature Communications|September 7, 2017
Phenotype-driven precision oncology as a guide for clinical decisions one patient at a timeShumei Chia, Joo-Leng Low, Xiaoqian Zhang, et al.
The Lancet. Oncology|January 18, 2025
Pembrolizumab with or without bevacizumab in platinum-resistant recurrent or metastatic nasopharyngeal carcinoma: a randomised, open-label, phase 2 trialWan-Qin Chong, Jia-Li Low, Joshua K Tay, et al.
Cell Reports. Medicine|April 5, 2025
CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancerShumei Chia, Justine Jia Wen Seow, Rafael Peres da Silva, et al.
Nature Genetics|June 30, 2022
Single-cell and bulk transcriptome sequencing identifies two epithelial tumor cell states and refines the consensus molecular classification of colorectal cancerIgnasius Joanito, Pratyaksha Wirapati, Nancy Zhao, et al.
Pageof 2